Neutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses
Our findings provide valuable population-based comparison of NAb levels elicited by different vaccines following primary inoculation and booster doses. Notably, the mRNA vaccine exhibited a strong primary and initial booster NAb response against SARS-CoV-2.
Authors
- Ingrid Horbach (ORCID: https://orcid.org/0000-0003-0889-6991)
- Thalia Medeiros (ORCID: https://orcid.org/0000-0002-5642-4027)
- Paolla Beatriz Almeida Pinto
- Alexandre Tadeu Paulino (ORCID: https://orcid.org/0000-0001-7076-2797)
- Andrea T. Da Poian (ORCID: https://orcid.org/0000-0002-3969-704X)
- Beatriz L. L. Caetano
- Simone M. da Costa
- Aline Pereira
- Lorena O. Fernandes-Siqueira (ORCID: https://orcid.org/0000-0002-4219-7636)
- Agatha R. Pacheco
- Thiago Martins Machado (ORCID: https://orcid.org/0000-0002-6796-3683)
- Ada M. B. Alves (ORCID: https://orcid.org/0000-0002-5487-4032)
- Adriana de Souza Azevedo (ORCID: https://orcid.org/0000-0001-7401-5107)
- A. Lage
- Amanda Nascimento
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Fundação Oswaldo Cruz (BR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1603612
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Fundação Oswaldo Cruz